PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 22 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Ethanolic extract and ultra-highly diluted Condurango 30C showed ameliorating effects on benzo[a]pyrene-induced lung cancer in rats via caspase-3-mediated apoptosis [PMID:25780671, PMID:25780694].
In vitro studies show that Condurango extract and condurangogenin A induce ROS-dependent apoptosis and cell-cycle arrest [PMID:23807740, PMID:26389000].
In vitro studies suggest Gonolobus condurango may act as a histone deacetylase inhibitor (HDACi) in TNBC cell lines [PMID:40375313].
Pregnane glycosides from condurango cortex acted as differentiation inducers, transforming M1 cells into phagocytic cells [PMID:8004709].
Evidence summary
PubMed sources
- 1.PMID: 40375313 (2025) — Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study. · BMC complementary medicine and therapies
- 2.PMID: 26389000 (2015) — Condurango (Gonolobus condurango) Extract Activates Fas Receptor and Depolarizes Mitochondrial Membrane Potential to Induce ROS-dependent Apoptosis in Cancer Cells in vitro: CE-treatment on HeLa: a ROS-dependent mechanism. · Journal of pharmacopuncture
- 3.PMID: 25780677 (2013) — Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract. · Journal of pharmacopuncture
- 4.PMID: 26088552 (2015) — Condurango 30C Induces Epigenetic Modification of Lung Cancer-specific Tumour Suppressor Genes via Demethylation. · Forschende Komplementarmedizin (2006)
- 5.PMID: 23807740